WallStSmart

Atea Pharmaceuticals Inc (AVIR)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Atea Pharmaceuticals Inc generates 25800% more annual revenue ($192.18M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. AVIR earns a higher WallStSmart Score of 54/100 (C-).

AVIR

Buy

54

out of 100

Grade: C-

Growth: 8.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: 0.97

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVIR4 strengths · Avg: 10.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
295.2%10/10

Revenue surging 295.2% year-over-year

EPS GrowthGrowth
264.1%10/10

Earnings expanding 264.1% YoY

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

AVIR4 concerns · Avg: 3.0/10
Market CapQuality
$341.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AVIR

The strongest argument for AVIR centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 295.2% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : AVIR

The primary concerns for AVIR are Market Cap, Profit Margin, Operating Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

AVIR profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

AVIR is growing revenue faster at 295.2% — sustainability is the question.

AVIR generates stronger free cash flow (-46M), providing more financial flexibility.

Bottom Line

AVIR scores higher overall (54/100 vs 24/100) and 295.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Atea Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?